Dextran 40 reduces in vitro platelet aggregation in peripheral arterial disease

Platelets

Volumn 15, Issue 4, 2004, Pages 215-222

  Robless, P ^a   Okonko, D ^a   Mikhailidis, D P ^b   Stansby, G ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DEXTRAN; DEXTRAN 40; DIPYRIDAMOLE; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PADGEM PROTEIN;

ADULT; ARTERY DISEASE; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FRIEDMAN TEST; HUMAN; MALE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANK SUM TEST; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN; DEXTRANS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS;

EID: 3042701537     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100410001682814     Document Type: Article

References (40)

1. Gronwall A, Hint H, Ingelman B. Dextran plasma volume expanders: chemistry and biological activities. Bibl Haematol 1968; 29: 874-82.
2. Gelin L, Ingleman B. Rheomacrodex - a new dextran for rheological treatment of impaired capillary flow. Acta Chir Scand 1961; 122: 294-302.
3. Jansen H. Postoperative thromboembolism and its prevention with 500 ml dextran given during operation. With a special study of the venous flow pattern in the lower extremity. Acta Chir Scand 1972; 427(Suppl): 1-73.
4. Naylor A, Hayes P, Allroggen H, Lennard N, Gaunt M, Thompson M, et al. Reducing the risk of carotid surgery: a 7-year audit of the role of monitoring and quality control assessment. J Vasc Surg 2000; 32: 750-9.
5. Rutherford R, Jones D, Bergentz S-E, Bergqvist D, Karmody A, Dardik H, et al. The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass. J Vasc Surg 1984; 1: 765-73.
6. Bergqvist D. Dextran and haemostasis - a review. Acta Chir Scand 1982; 148: 633-40.
7. George J, Shattil S. The clinical importance of acquired abnormalities of platelet function. New Engl J Med 1991; 324: 27-39.
8. LaRosa C, Rohrer M, Benoit S, Rodino L, Barnard M, Michelson A. Human neutrophil cathepsin G is a potent platelet activator. J Vasc Surg 1994; 19: 306-19.
9. Valles J, Santos M, Aznar J, Osa A, Lago A, Cosin J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. Circulation 1998; 97: 350-55.
10. Schmitz G, Rothe G, Ruf A. et al. European working group on cell cycle analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-96.
11. Barradas M, O'Donoghue S, Mikhailidis D. Advantages of whole blood platelet aggregation measured by a cell counter (Coulter T-890) in drug evaluation. J Drug Dev 1992; 5(3): 155-6.
12. Robless P, Okonko D, Lintott P, Mansfield A, Mikhailidis D, Stansby G. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003; 25: 16-22.
13. Sobel M, Adelman B, Greenfield L. Dextran 40 reduces Heparin mediated platelet aggregation. J Surg Res 1985; 40: 382-7.
14. Shattil S, Cunningham M, Hoxie J. Detection of activated platelets in whole blood using activation dependant monoclonal antibodies and whole blood flow cytometry. Blood 1987; 70: 307-15.
15. Robless P, Tegos T, Okonko D, Mansfield A, Nicolaides A, Mikhailidis D, et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 2002; 13: 231-9.
16. Karl-Heinz L, Dormandy J, Jaeger K, Stuerzebecher C, Hiatt W. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: Clinical Trial Methodology. Circulation 1999; 100: e75-e81.
17. McDaniel M, Pearce W, Yao J, Rossi E, Fahey V, Green D, et al. Sequential changes in coagulation and platelet function following femorotibial bypass. J Vasc Surg 1984; 1: 261-8.
18. Robless P, Mikhailidis D, Stansby G. A systematic review of antiplatelet therapy for prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.
19. Antithrombotic Trialist's. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324(7329): 71-86.
20. Lennard N, Smith J, Hayes P, Abbott R, London N, Bell P, et al. Transcranial Doppler directed Dextran therapy in the prevention of post-operative carotid artery thrombosis: 3 hrs monitoring is as effective as 6 hrs. Eur J Vasc Endovasc Surg 1999; 17: 301-5.
21. Nazzal M, Owunwanne A, Christenson J. Direct platelet effect of low molecular weight dextran in small calibre PTFE grafts. Eur J Vasc Surg 1991; 5: 169-72.
22. Ernst E, Kollar L, Matrai A. Double-blind trail of Dextran-haemodilution vs.Placebo in claudicants. J Int Med 1990; 227: 19-24.
23. Bergqvist D, Bergentz S. The role of dextran in severe ischaemic extremity disease and arterial reconstructive surgery. A review. VASA 1983; 12: 213-7.
24. Aberg M, Hedner U, Bergentz S-E. Effect of dextran on factor VIII (antihaemophilic factor) and platelet function. Ann Surg 1979; 189: 243-7.
25. Miller C, Lim R. Dextran as a modulator of immune and coagulation activities in trauma patients. J Surg Res 1985; 39: 183-91.
26. Noorman F, Barrett-Bergshoeff M, Bekkers M, Emeis J, Rijken D. Effect of dextran-40 on mannose receptor-mediated clearance of tissue-type plasminogen activator. Thromb Haemost 1997; 78: 1249-54.
27. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J-i. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31(3): 591-5.
28. Steinbauer M, Harris A, Messmer K. Effects of dextran on microvasular ischaemia-reperfusion injury in striated muscle. Am J Physiol 1997; 272: H1710-H1716.
29. Peyton B, Rohrer M, Furman M, Barnard M, Rodino L, Benoit S, et al. Patients with venous stasis ulceration have increased monocyte-platelet aggregation. J Vasc Surg 1998; 27: 1109-15.
30. Ruggeri Z. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: 611-6.
31. Batlle J, Del Rio F, Lopez-Fernandez M, Martin R, Lopez B. Effect of dextran on factor VIII/von Willebrand factor structure and function. Thromb Haemost 1985; 54: 697-9.
32. Lindbland B, Jensen N, Dougan P, Bergvist D. Does dextran 40 reduce early graft thrombogenicity? An experimental investigation on patency and platelet deposition on prosthetic graft materials in sheep. Eur J Vasc Surg 1990; 4: 341-44.
33. Shoenfeld N, Eldrup-Jorgensen J, Connolly R, Callow A, Valeri C, Ramberg K, et al. The effect of low molecular weight dextran on platelet deposition onto prosthetic materials. J Vasc Surg 1987; 5: 76-82.
34. Garrett K, Pautler S, Johnson P. The inability of low molecular weight dextran, aspirin and prostaglandin EI to inhibit monolayer platelet adhesion to polythylene. J Lab Clin Med 1993; 121: 141-8.
35. Fatkin D, Loupas T, Low J, Feneley M. Inhibition of red cell aggregation prevents spontaneous echocardiographic contrast formation in human blood. Circulation 1997; 96(3): 889-96.
36. Engeset J, Stalker A, Matheson N. Effects of dextran 40 on red cell aggregation in rabbits. Cardiovasc Res 1967; 1: 379-84.
37. Engeset J, Stalker A, Matheson N. Effects of dextran 40 on erythrocyte aggregation. Lancet 1966; i: 1124-1127.
38. Jan K-M, Usami S, Chien S. The disaggregation effect of dextran 40 on red cell aggregation in macromolecular suspensions. Biorheology 1982; 19: 543-54.
39. Maeda N, Shiga T. Inhibition and acceleration of erythrocyte aggregation induced by small macromolecules. Biochim Biophys Acta 1985; 843: 128-36.
40. Kroemer H, Haass A, Muller K, Jager H, Wagner E, Heimburg P, et al. Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5. Eur J Clin Pharmacol 1987; 31: 705-10.